Ocriplasmin injection showed high rate of success in select VMT patients
LISBON, Portugal — Real-life data of a selected, homogeneous group of patients with vitreomacular traction only, treated by a single injection of ocriplasmin, showed higher efficacy compared with MIVI-TRUST data.
“We had an overall success rate, in terms of resolution of the traction, in 52% of the patients, compared with the 26% rate of the MIVI-TRUST. Patients with focal traction did even better, with a 61% success rate,” Peter Szurman, MD, said in an industry-sponsored symposium at the Controversies in Ophthalmology meeting.
The study on Jetrea (ocriplasmin, ThromboGenics/Alcon) was conducted in a clinic in Germany and enrolled 23 eyes of 22 patients with VMT. Eighteen eyes had focal adhesion, and five had broad adhesion. The follow-up was 4 weeks.
“Ocriplasmin worked even better than expected in VMT and showed a remarkably higher success rate of 61% vs. 20% in focal vs. broad adhesion,” Szurman said.
A significant decrease in macular thickness and increase in vision were also obtained. Eyes with focal traction again had the best results, with a mean gain of more than two lines.
“Improvement was up to four lines in some cases. There were eyes that lost one line but will be re-evaluated in the long term,” Szurman said.
In his opinion, although not all cases are successful, ocriplasmin should be offered to patients as an alternative to wait-and-see.
“It is true that traction might resolve spontaneously, but patients are, in the meantime, disturbed by image distortion, which affects performance at work and life quality,” he said.
Disclosure: Szurman received a speaker’s fee from Alcon.